These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 35508695)

  • 21. Azacitidine versus decitabine in patients with refractory anemia with excess blast-Results of multicenter study.
    Salim O; Toptas T; Avsar E; Yucel OK; Ozturk E; Ferhanoglu B; Geduk A; Mehtap O; Tombak A; Tiftik EN; Deveci B; Kurtoglu E; Kara O; Atagunduz IK; Tuglular TF; Undar L
    Leuk Res; 2016 Jun; 45():82-9. PubMed ID: 27107658
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact of the relative dose intensity on survival of patients with high-risk myelodysplastic syndromes treated with Azacitidine.
    Laribi K; Bolle D; Alani M; Ghnaya H; Besançon A; Farhi J; Mheidly K; Denizon N; Baugier de Materre A
    Cancer Med; 2019 May; 8(5):2188-2195. PubMed ID: 30993891
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treatment with low-dose cytosine arabinoside followed by administration of macrophage colony-stimulating factor prolongs the survival of patients with RAEB, RAEB-T, or leukemic phase myelodysplastic syndrome: a pilot study.
    Fukuhara T; Miyake T; Maekawa I; Kurosawa M; Suzuki S; Noto S; Mori A; Chiba K; Toyoshima T; Hirano T; Morioka M; Tsutsumi Y; Okabe M; Kakinoki Y
    Int J Hematol; 2000 Jun; 71(4):366-71. PubMed ID: 10905057
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Predicting outcome in higher-risk myelodysplastic syndrome patients treated with azacitidine.
    Bouchla A; Thomopoulos TP; Papageorgiou SG; Apostolopoulou C; Loucari C; Mpazani E; Pappa V
    Epigenomics; 2021 Jul; 13(14):1129-1143. PubMed ID: 34291653
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Azacitidine for the treatment of myelodysplastic syndrome, chronic myelomonocytic leukaemia and acute myeloid leukaemia.
    Edlin R; Connock M; Tubeuf S; Round J; Fry-Smith A; Hyde C; Greenheld W
    Health Technol Assess; 2010 May; 14 Suppl 1():69-74. PubMed ID: 20507806
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Successful treatment of a 74-year-old man with refractory anemia with excess of blasts in transformation (RAEB in T) by low-dose Ara-C injection].
    Wataya S; Sudou H; Sakamaki I; Wano Y; Ueda T; Nakamura T
    Nihon Ronen Igakkai Zasshi; 1995 Jun; 32(6):438-41. PubMed ID: 7563939
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and safety of a 5-day regimen of azacitidine for patients with high-risk myelodysplastic syndromes.
    Fujimaki K; Miyashita K; Kawasaki R; Tomita N
    Eur J Haematol; 2016 Sep; 97(3):228-31. PubMed ID: 26613362
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Effective azacitidine treatment for myelodysplastic syndrome transformed from essential thrombocythemia].
    Iizuka H; Yoshimi A; Yamamoto G; Masuda A; Nannya Y; Ichikawa M; Yatomi Y; Kurokawa M
    Rinsho Ketsueki; 2013 May; 54(5):468-72. PubMed ID: 23727686
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine.
    Itzykson R; Thépot S; Quesnel B; Dreyfus F; Beyne-Rauzy O; Turlure P; Vey N; Recher C; Dartigeas C; Legros L; Delaunay J; Salanoubat C; Visanica S; Stamatoullas A; Isnard F; Marfaing-Koka A; de Botton S; Chelghoum Y; Taksin AL; Plantier I; Ame S; Boehrer S; Gardin C; Beach CL; Adès L; Fenaux P;
    Blood; 2011 Jan; 117(2):403-11. PubMed ID: 20940414
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Aberrant promoter methylation of Dab2 gene in myelodysplastic syndrome.
    Yang Y; Zhang Q; Xu F; Chang C; Li X
    Eur J Haematol; 2012 Dec; 89(6):469-77. PubMed ID: 23005040
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Rigosertib versus best supportive care for patients with high-risk myelodysplastic syndromes after failure of hypomethylating drugs (ONTIME): a randomised, controlled, phase 3 trial.
    Garcia-Manero G; Fenaux P; Al-Kali A; Baer MR; Sekeres MA; Roboz GJ; Gaidano G; Scott BL; Greenberg P; Platzbecker U; Steensma DP; Kambhampati S; Kreuzer KA; Godley LA; Atallah E; Collins R; Kantarjian H; Jabbour E; Wilhelm FE; Azarnia N; Silverman LR;
    Lancet Oncol; 2016 Apr; 17(4):496-508. PubMed ID: 26968357
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Azacitidine with or without Entinostat for the treatment of therapy-related myeloid neoplasm: further results of the E1905 North American Leukemia Intergroup study.
    Prebet T; Sun Z; Ketterling RP; Zeidan A; Greenberg P; Herman J; Juckett M; Smith MR; Malick L; Paietta E; Czader M; Figueroa M; Gabrilove J; Erba HP; Tallman MS; Litzow M; Gore SD;
    Br J Haematol; 2016 Feb; 172(3):384-91. PubMed ID: 26577691
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Azacytidine for the treatment of myelodysplastic syndromes in the elderly.
    Diez Campelo M; Delgado RG; Molias AC; Sanchez JF
    Adv Ther; 2011 Mar; 28 Suppl 2():10-5. PubMed ID: 21431505
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prolonged administration of azacitidine with or without entinostat for myelodysplastic syndrome and acute myeloid leukemia with myelodysplasia-related changes: results of the US Leukemia Intergroup trial E1905.
    Prebet T; Sun Z; Figueroa ME; Ketterling R; Melnick A; Greenberg PL; Herman J; Juckett M; Smith MR; Malick L; Paietta E; Czader M; Litzow M; Gabrilove J; Erba HP; Gore SD; Tallman MS
    J Clin Oncol; 2014 Apr; 32(12):1242-8. PubMed ID: 24663049
    [TBL] [Abstract][Full Text] [Related]  

  • 35. No clear survival benefit of azacitidine for lower-risk myelodysplastic syndromes: A retrospective study of Nagasaki.
    Toriyama E; Hata T; Yokota KI; Chiwata M; Kamijo R; Hashimoto M; Taguchi M; Horai M; Matsuo M; Matsuo E; Takasaki Y; Kawaguchi Y; Itonaga H; Sato S; Ando K; Sawayama Y; Taguchi J; Imaizumi Y; Tsushima H; Jo T; Yoshida S; Moriuchi Y; Miyazaki Y
    Cancer Sci; 2020 Dec; 111(12):4490-4499. PubMed ID: 32939867
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Overall survival of myelodysplastic syndrome patients after azacitidine discontinuation and applicability of the North American MDS Consortium scoring system in clinical practice.
    Clavio M; Crisà E; Miglino M; Guolo F; Ceccarelli M; Salvi F; Allione B; Ferrero D; Balleari E; Finelli C; Poloni A; Selleri C; Danise P; Cilloni D; Di Tucci AA; Cametti G; Freilone R; Fanin R; Bigazzi C; Zambello R; Crugnola M; Oliva EN; Centurioni R; Alesiani F; Catarini M; Castelli A; Abbadessa A; Capalbo SF; Musto P; Angelucci E; Santini V
    Cancer; 2021 Jun; 127(12):2015-2024. PubMed ID: 33739457
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Epigenetic priming with decitabine followed by low dose idarubicin and cytarabine in acute myeloid leukemia evolving from myelodysplastic syndromes and higher-risk myelodysplastic syndromes: a prospective multicenter single-arm trial.
    Zhou X; Mei C; Zhang J; Lu Y; Lan J; Lin S; Zhang Y; Kuang Y; Ren Y; Ma L; Wei J; Ye L; Xu W; Li K; Lu C; Jin J; Tong H
    Hematol Oncol; 2020 Oct; 38(4):531-540. PubMed ID: 32469434
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impact of azacitidine before allogeneic stem-cell transplantation for myelodysplastic syndromes: a study by the Société Française de Greffe de Moelle et de Thérapie-Cellulaire and the Groupe-Francophone des Myélodysplasies.
    Damaj G; Duhamel A; Robin M; Beguin Y; Michallet M; Mohty M; Vigouroux S; Bories P; Garnier A; El Cheikh J; Bulabois CE; Huynh A; Bay JO; Legrand F; Deconinck E; Fegueux N; Clement L; Dauriac C; Maillard N; Cornillon J; Ades L; Guillerm G; Schmidt-Tanguy A; Marjanovic Z; Park S; Rubio MT; Marolleau JP; Garnier F; Fenaux I; Yakoub-Agha I
    J Clin Oncol; 2012 Dec; 30(36):4533-40. PubMed ID: 23109707
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Higher infection rate after 7- compared with 5-day cycle of azacitidine in patients with higher-risk myelodysplastic syndrome.
    Ofran Y; Filanovsky K; Gafter-Gvili A; Vidal L; Aviv A; Gatt ME; Silbershatz I; Herishanu Y; Arad A; Tadmor T; Dally N; Nemets A; Rouvio O; Ronson A; Herzog-Tzarfati K; Akria L; Braester A; Hellmann I; Yeganeh S; Nagler A; Leiba R; Mittelman M; Merkel D
    Clin Lymphoma Myeloma Leuk; 2015 Jun; 15(6):e95-9. PubMed ID: 25819366
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cutaneous adverse events induced by azacitidine in myelodysplastic syndrome patients: Case reports and a lesson from published work review.
    Shimoda-Komatsu Y; Mizukawa Y; Takayama N; Ohyama M
    J Dermatol; 2020 Apr; 47(4):363-368. PubMed ID: 32056290
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.